Pharmacological Approaches in Osteoarthritis Management

Osteoarthritis is managed primarily through pharmacological interventions that target pain, inflammation and disease progression. First‐line therapies include simple analgesics and non‐steroidal anti‐inflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis to relieve discomfort. Beyond symptom relief, symptomatic slow‐acting drugs for osteoarthritis (SYSADOAs) such as glucosamine and chondroitin sulfate aim to support cartilage matrix integrity, while disease‐modifying osteoarthritis drugs (DMOADs) seek to alter underlying pathophysiology by inhibiting cytokines or matrix‐degrading enzymes. Recent advances have focused on small‐molecule inhibitors of interleukin pathways, anthraquinone derivatives with multi‐pathway anti‐inflammatory actions, and bisphosphonates to modulate subchondral bone remodelling. Combination regimens—pairing oral agents with targeted physical or mineral‐based therapies—are under evaluation to optimise efficacy and minimise adverse effects. Ongoing research emphasises global applicability, cost-effectiveness and precision medicine approaches to tailor pharmacotherapy to individual phenotypes of osteoarthritis.

Research from Nature Portfolio

Recent studies have demonstrated that adjunctive therapies can potentiate conventional pharmacological regimens. In a preclinical model, thermal mineral bathing combined with diclofenac produced synergistic anti-inflammatory, chondroprotective and anti-apoptotic effects. Treated joints showed reduced synovial inflammation and cartilage degradation scores alongside increased bone mineral density, suggesting that integrating complementary modalities with established NSAIDs may enhance structural preservation and functional recovery.

Pharmacological Approaches in Osteoarthritis Management publication trend

The graph below shows the total number of articles in pharmacological approaches in osteoarthritis management across all publications each year (not limited to Nature Index journals).

Technical terms

Chondrocyte: Cartilage cell responsible for synthesising and maintaining the extracellular matrix within articular cartilage.

Disease-Modifying Osteoarthritis Drug (DMOAD): Agent designed to interfere with the pathophysiological processes of osteoarthritis rather than solely alleviating symptoms.

Effusion-Synovitis: Accumulation of fluid and inflammatory cells within the synovial membrane, contributing to joint pain and structural progression in osteoarthritis.

Matrix Metalloproteinases (MMPs): Enzyme family that degrades components of the extracellular matrix, accelerating cartilage breakdown in osteoarthritis.

Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA): A class of oral compounds, including glucosamine and chondroitin, thought to appear gradually over weeks to alleviate symptoms and support joint structure.

References

1. Anti-inflammatory Effects and Mechanisms of Rhein, an Anthraquinone Compound, and Its Applications in Treating Arthritis: A Review. Natural Products and Bioprospecting (2020).
2. Mechanical exposure and diacerein treatment modulates integrin-FAK-MAPKs mechanotransduction in human osteoarthritis chondrocytes. Cellular Signalling (2018).
3. Effects of Balneotherapy in Jeju Magma-Seawater on Knee Osteoarthritis Model. Scientific Reports (2020).
4. Efficacy of glucosamine plus diacerein versus monotherapy of glucosamine: a double-blind, parallel randomized clinical trial. Arthritis Research & Therapy (2016).